The inhibitory potency and duration of action of single doses of aspirin B.P., claradin (a low sodium effervescent preparation of acetylsalicylic acid) and aloxiprin (an aluminium co-polymer of acetylsalicylic acid) on platelet release reaction induced by adenosine diphosphate (ADP) were studied in seventeen volunteers. Aspirin B.P. and claradin at 300 mg and 150 mg inhibited release reaction in all subjects within 24 hr; 75 mg was effective only in some subjects. Aloxiprin gave less marked response and a dose of 300 mg was required to inhibit the effect in all volunteers. Where occurring, inhibition of release reaction persisted for three days after treatment with all preparations and restoration to normal occurred in most subjects by the sixth day.
Introduction
During the past decade considerable research activity has centred on drugs which inhibit platelet function. Mustard and Packham (1970) have comprehensively reviewed all aspects of platelet adhesion and aggregation and their clinical implications. It has long been suggested that pharmacological agents which inhibit platelet adhesion and aggregation may Correspondence: Dr R. M. Rowan, Department of Haematology, Royal Infirmary, Glasgow. be clinically useful in the prevention of thrombotic incidents (McDonald and Edgill, 1959; Breddin, 1968; Bygdeman and Wells, 1969; Renaud and Godu, 1970; Weiss, Danese and Valeti, 1970; Wood, 1972; Breddin, 1973) . Inhibitors of platelet function, both naturally occurring substances and drugs, may be divided into three categories, namely (a), selective inhibitors of specific aggregating agents; (b), general inhibitors of primary aggregation; (c) specific inhibitors of secondary aggregation (Mills, 1972) . This last group includes acetylsalicylic acid (ASA), a drug which appears promising as an effective and safe anti-aggregant (O'Brien, 1968a; Weiss, Aledort and Kochwa, 1968; Renaud and Godu, 1970; Stuart, 1970; Weiss et al., 1970) .
Clearly, a therapeutic trial of salicylates is justified in individuals at risk from arterial thrombosis and it has even been suggested that such a trial be extended to all men over the age of 20 years and all women over the age of 40 years on a long term basis (Wood, 1972) . Exceptions to this would be persons suffering from haemostatic defects, allergy to salicylates, and a previous history of bleeding from the gastrointestinal tract or other system.
It is the purpose of this paper to report studies designed to assess the potency and duration of inhibition of platelet release reaction produced by various pharmaceutical formulations of ASA over a spectrum of dosage levels in normal volunteers. Furthermore, since gastro-intestinal haemorrhage is a well recognized complication of prolonged salicylate ingestion, it becomes mandatory to define the minimum effective drug dosage (Andra'ssy et al., 1973) .
Subjects and methods
For each of the studies, volunteers were obtained from two centres, Glasgow and Slough. (Rowan, 1973) to ensure that the samples contained between 250,000 and 400,000 platelets/ml.
Platelet aggregation was measured by the turbidimetric method of Born (1962) and O'Brien (1962) using either a Bryston aggregometer (Glasgow) or an Eel Model 169 aggregometer (Slough). Both instruments measure changes in optical density of PRP at 37°C as platelets aggregate. Since different volumes of PRP were used in the two instruments, an arithmetical correction factor was applied to give comparable results. After pre-warming at 37'C for 2 min, the PRP to be tested was added to the reaction cuvette of the aggregometer and there continuously agitated by a magnetic stirrer at 1100 rev/min. Changes in optical density were recorded on a Servoscribe single channel recorder which had previously been adjusted to give a maximal optical density reading on the subject's PRP and a fullscale deflection (1 mV) with the corresponding platelet poor plasma.
The sodium salt of ADP (Sigma) was dissolved in distilled water to a concentration of 1 mmol/l. This stock solution was stored in aliquots at -20°C and working solutions were prepared on the day of use by further dilution in barbitol-buffered saline at pH 7 35. In each volunteer, the minimum concentration of ADP which produced a secondary wave of platelet aggregation was taken as the base-line for all subsequent studies.
All volunteers selected demonstrated reproducible biphasic platelet aggregation in citrated PRP in response to exogenous ADP. There were 140 normal subjects who had previously been studied and the lowest concentration of ADP required to induce secondary platelet aggregation ranged from 0-5-1 8 ,umol/l, levels which were in broad agreement with those reported by Hardisty et al. (1970 
Results

First study
The results are summarized in Table 1 in terms of the number of times secondary aggregation did not occur on the first, third and sixth days after ASA ingestion for each preparation at each dose level. In the Glasgow volunteers no significant difference Glasgow Aspirin B.P. 9 7 4 9 9 6 9 9 7 9 Volunteers Claradin 9 8 1 9 9 6 9 9 3 Aloxiprin 8 5 1 9 9 5 9 9 4 Slough Aspirin B.P. 5 3 0 8 6 2 8 6 0 8 Volunteers Claradin 7 5 2 8 5 1 8 5 2 Aloxiprin 2 6 0 5 3 2 8 4 1 was noted between subjects or treatments. The responses, however, at 75 mg were significantly less than those of 150 mg and 300 mg (P< 0 05); there was evidence of a levelling of dose response at 150 mg. In the Slough volunteers the results were more variable and large differences were noted between the subjects and treatments. The treatment differences arose mainly from the reduced response to aloxiprin. As in the Glasgow results, the responses after 75 mg were significantly less (P< 0 05) than at the other two doses and there was an indication of levelling in the dose response curve at 150 mg. All subjects taking aspirin B.P. and claradin at the 300 mg and 150 mg dose levels demonstrated inhibition of secondary aggregation after 24 hr. The duration of inhibition differed in individuals but this was presumed to be due to variation in platelet turnover. Some subjects demonstrated an effect for 10 days. Aspirin B.P. produced inhibition of platelet aggregation in excess of 72 hr in sixteen of seventeen subjects studied and claradin in fifteen of seventeen subjects. With aloxiprin, while all volunteers demonstrated inhibition of secondary aggregation at 300 mg, persistence of biphasic reaction occurred in two subjects at 150 mg and in three subjects at 75 mg. All Glasgow volunteers, if showing inhibition, did so 24 hr after commencing treatment. The situation differed with the Slough volunteers in that on seven occasions (aloxiprin 75 mg x 5, aloxiprin 150 mg x 1, claradin 75 mg x 1) secondary aggregation persisted at 24 hr but was inhibited at 72 hr (Fig. 1 ). 
Second study
Using claradin in a dose of 50 mg daily, all subjects show inhibition of secondary aggregation but induction occurred at different rates, Slough volunteers taking longer than Glasgow volunteers (Table 2) . 
Discussion
Evidence continues to accumulate implicating the platelet in the initiation of arterial thrombus formation. Platelets rapidly adhere to exposed collagen in the arterial tree and subsequently undergo release action (Mustard, Rowsell and Murphy, 1966) . The ADP liberated causes other platelets to aggregate which in turn sets up a chain reaction. Thus, drugs which interfere with this process may well prevent thrombus formation.
Many common drugs impair platelet aggregation in vitro (Mustard et al., 1966; Evans et al., 1967; Mills and Roberts, 1967; Weiss et al., 1968) but ASA has been the most widely studied. During these studies, a wide range of doses has been used varying from 150 to 3600 mg daily (O'Brien, 1968a, b; Weiss et al., 1968; Zucker and Peterson, 1968; Stuart, 1970; Hirsch et al., 1973 ). However, above 150 mg, the degree of inhibition of platelet aggregation does not increase (Bjornson and Eika, 1973) .
The mechanism whereby ASA affects platelet function is incompletely defined. The observation that platelets can remain abnormal for several days after the ingestion of a single dose of ASA suggests that platelets are permanently affected by the drug and that restoration to normal probably represents the appearance of a new platelet population. Rosenberg et al. (1971) have demonstrated that platelets are acetylated by ASA probably via a mechanism involving the membrane protein. This will affect the physico-chemical properties of the platelet membrane protein which could account for the inhibition of secondary aggregation. An alternative or additional explanation is afforded by the work of Vargaftig and Zirinis (1973) who found that ASA and other anti-inflammatory drugs inhibit the production of a cyclic endoperoxide intermediate formed during the biosynthesis of prostaglandins from arachidonic acid in human and rabbit platelets. They suggest that this intermediate is responsible for platelet aggregation induced by collagen and that ADP released during the process plays an essential role.
ASA is absorbed from all parts of the gastrointestinal tract including the stomach. While initial absorption of ASA takes place across the gastric mucosa, the major site of absorption appears to be the proximal portion of the small intestine (Levy, 1961) . This is the result of the interaction of a num- (Cummings, Martin and Renton, 1971 
